Becton Dickinson Gains Positive Outlook with Buy Rating and $233 Target: Focus on MedTech Operations

Citi reinstates coverage of Becton Dickinson (BDX) with a Buy rating and a $233 price target. The company's strategic divestiture of its LifeSciences Bioprocessing segment is seen as a positive move towards focusing on core MedTech operations. BDX's financial metrics indicate a stable growth trajectory with room for operational efficiency improvements. The company's valuation metrics suggest a mixed picture, and analyst sentiment remains positive with a recommendation score of 2.5. Technical indicators suggest neutral momentum. Overall, BDX is well-positioned for future growth, albeit with some cautionary notes regarding financial stress and insider activity.